lundi 5 novembre 2018

Onco Actu du 5 novembre 2018

2.4 Etiologie - Portables, ondes e-m

Mobile phones and cancer: misleading headlines fail to mention rats [Cancer Research UK]

Statement from Jeffrey Shuren, M.D., J.D., Director of the FDA’s Center for Devices and Radiological Health on the National Toxicology Program’s report on radiofrequency energy exposure [FDA]

Study of Cellphone Risks Finds ‘Some Evidence’ of Link to Cancer, at Least in Male Rats [NY Times]

Mobile phone cancer link in rats – Expert Reaction [Science Media Centre]

What Does Bombarding Rodents With Cell Phone Radiation Tell Us About Risks To Humans? [Forbes]

3.1.1 Prévention - Tabac - e-cigs

Statement from FDA Commissioner Scott Gottlieb, M.D., on meetings with industry related to the agency’s ongoing policy commitment to firmly address rising epidemic rates in youth e-cigarette use [FDA]

3.3 Prévention - Vaccins

HPV Vaccination for Cancer Prevention: Progress, Opportunities, and a Renewed Call to Action [President's Cancer Panel]

4. Dépistage, diagnostic et pronostic

Glowing chemical 'could aid brain cancer surgery' [BBC News]

'Fluorescent marker' could help surgeons remove deadly brain tumours [The Telegraph]

4.12 Biopsies liquides

Circulating Tumor DNA–Defined Minimal Residual Disease in Solid Tumors: Opportunities to Accelerate the Development of Adjuvant Therapies [Journal of Clinical Oncology]

4.3 Dép., diag. & prono. - Industriels

DNA sequencing giant Illumina just bought rival Pac Bio for $1.2 billion — here's why [CNBC]

DNA Sequencing Giant Illumina Will Buy Pacific Biosciences For $1.2 Billion – Exclusive CEO Interview [Forbes]

Illumina to Acquire Pacific Biosciences for Approximately $1.2 Billion, Broadening Access to Long-Read Sequencing and Accelerating Scientific Discovery [Illumina]

Illumina Set to Acquire “Long-Read” DNA Sequencer PacBio for $1.2B [Xconomy]

4.7 Dép., diag. & prono. - Col de l'utérus

Computer simulation suggests testing for HPV first could mean cervical screening can be stopped earlier [Cancer Research UK]

4.9 Dép., diag. & prono. - Sein

A Prognostic Model May Predict Survival in African-American Women with Breast Cancer [AACR]

Women Carrying Rare Breast Cancer Variants Are More Likely to Develop Interval Breast Cancers [AACR]

5. Traitements

Minimally invasive radical hysterectomy may increase death risk in patients with early-stage cervical cancer [Mass. Geneal Hospital]

For Cervical Cancer Patients, Less Invasive Surgery Is Worse For Survival [NPR]

Studies Warn Against Minimally Invasive Surgery for Cervical Cancer [NY Times]

More deaths seen for less invasive cervical cancer surgery [AP]

5.10 Traitements - Essais

U.K. House of Commons committee report calls for more transparency on clinical trials [FierceBiotech]

5.12 Immunothérapies

Specific CD8 T cell states may indicate response to immune checkpoint therapy for melanoma [Mass. General Hospital]

A cure for cancer: how to kill a killer [The Guardian]

5.12.4 Immunothérapies - Essais

As rivals press in, Stanford spinout Forty Seven burnishes its prospects from an impressive PhIb [EndPoints]

5.12.6 Immunothérapies - AMM

FDA approves pembrolizumab in combination with chemotherapy for first-line treatment of metastatic squamous NSCLC [FDA]

Merck beats out Roche with yet another Keytruda lung cancer approval [FiercePharma]

5.2 Pharma

AbbVie Announces Positive Results from CLL14, a Phase 3 Trial Evaluating a Venetoclax Combination as First-Line Therapy with a Fixed Duration of Treatment in Patients with Chronic Lymphocytic Leukemia [AbbVie]

Phase III data showed that Venclexta/Venclyxto plus Gazyva/Gazyvaro reduced the risk of disease worsening or death in people with previously untreated chronic lymphocytic leukaemia with co-morbidities [Roche]

AbbVie, Roche combo treatment meets main goal of leukemia trial [Reuters]

5.3.4 Traitements - AMM (FDA, EMA,...)

Pfizer racks up its third cancer drug OK in 2 months, but is it enough to replace regular price hikes? [EndPoints]

U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC [Pfizer]

FDA approves Pfizer's treatment for certain lung cancer patients [Reuters]

Yet another AbbVie-Roche regimen, this time with Venclexta and Gazyva, hits its marks in CLL [FiercePharma]

AbbVie Receives European Commission Approval of VENCLYXTO® (venetoclax) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy [AbbVie]

Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia [Roche]

5.8.2 ASH - Pharma

Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology [Novartis]

Amgen To Present New Data Showcasing Extensive Portfolio And Exciting Early Oncology Pipeline At ASH 2018 [Amgen]

Takeda to Present Data During 60th American Society of Hematology Annual Meeting on Wide Array of Treatment Needs for Blood Cancers [Takeda]

Roche to present new data from its industry-leading haematology portfolio at the American Society of Hematology 2018 Annual Meeting [Roche]

Janssen Shows Commitment to Advancing the Science and Treatment of Blood Cancers and Related Conditions With More Than 80 ASH 2018 Data Presentations From Differentiated Oncology and Cardiovascular Portfolios [Janssen]

6.1 Observation

Prostate cancer surgery and radiation tied to antidepressant use [Reuters]

6.10.1 Politiques (USA)

Drug price controls? A good idea, but don't bet on it [Modern Healthcare]

6.11 Patients

She Chose To 'Go Flat' And Wants Other Breast Cancer Survivors To Know They Can Too [NPR]

6.12 Ethique

Could an ELF have saved Baselga? [Bioethics]

6.5 Médecines alternatives/complémentaires

Belief in alternative cancer cures: We have a lot of work to do to combat quackery [Respectful Insolence]